Polaryx Therapeutics Common Stock Accounts Payable

Polaryx Therapeutics Common Stock (PLYX) currently reports a accounts payable of $680K as of June 2026. That compares with $160K in the prior-year period — up 332.3% year over year. Use the charts on this page to explore Polaryx Therapeutics Common Stock's accounts payable history and peer comparisons.

Polaryx Therapeutics Common Stock's accounts payable increased from $160K to $680K — a 332.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Polaryx Therapeutics Common Stock reported $680K in accounts payable as of June 2026. That compares with $160K in the prior-year period — up 332.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $680K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Polaryx Therapeutics Common Stock, and consider following PLYX for alerts when major investors trade the stock.

Polaryx Therapeutics Common Stock is classified in the Healthcare sector. On accounts payable, it currently shows $680K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLYX with unrelated industries.